The U.S. Supreme Court is set to consider a case that has caught the attention of many southern California drug recall attorneys due to its potentially far-reaching consequences for patients who are harmed by generic medications, according to a recent article in The New York Times.
The case the Supreme Court will hear involves a New Hampshire woman who suffered severe injuries after experiencing a rare allergic reaction to sulindac, a non-steroidal anti-inflammatory medication (NSAID) often prescribed to treat mild to moderate pain. The sulindac she took was manufactured by Mutual Pharmaceutical Company and was a generic version of a medication originally marketed by Merck under the brand name Clinoril. Clinoril was approved by the Food and Drug Administration (FDA) in 1978. Read the rest »